Evidence map›Paper›PMID 25829376›Full record

ArticleSchizophrenia bulletin2015

Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.

Marco Colizzi, Conrad Iyegbe, John Powell, Gianluca Ursini, Annamaria Porcelli, Aurora Bonvino, Paolo Taurisano, Raffaella Romano, Rita Masellis, Giuseppe Blasi and 9 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia bulletin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 4 pooled it
9.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. The Autism-Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System.International journal of environmental research and public health · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Interaction BetweenNeurology international · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Cannabis Pharmacogenomics: A Path to Personalized Medicine.Current issues in molecular biology · 2023
    Review
  13. Article
  14. Influence ofInternational journal of environmental research and public health · 2022
    Article
  15. Review
  16. Article
  17. Cannabis and Depression.Advances in experimental medicine and biology · 2021
    Review
  18. Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 4 countries.

Marco ColizziDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
Conrad IyegbeDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
John PowellDepartment of Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
Gianluca UrsiniDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy; Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MA;
Annamaria PorcelliDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy;
Aurora BonvinoDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy;
Paolo TaurisanoDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy;
Raffaella RomanoDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy;
Rita MasellisDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy;
Giuseppe BlasiDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy;
Craig MorganDepartment of Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
Katherine AitchisonMRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
Valeria MondelliDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
Sonija LuziDepartment of Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
Anna KolliakouNational Institute for Health Research Maudsley Biomedical Research Centre and Dementia Unit, London, UK;
Anthony DavidDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
Robin M MurrayDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;
Alessandro BertolinoDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy; pRED, NORD DTA, F. Hoffman-La Roche Ltd., Basel, Switzerland.
Marta Di FortiDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; marta.diforti@kcl.ac.uk.
King's College London · GBUniversity of Bari Aldo Moro · ITNational Institute for Health Research · GBRoche (Switzerland) · CH

Funding

Department of HealthMedical Research Council MR/M008436/1
6 · The paper itself

Abstract

Both cannabis use and the dopamine receptor (DRD2) gene have been associated with schizophrenia, psychosis-like experiences, and cognition. However, there are no published data investigating whether genetically determined variation in DRD2 dopaminergic signaling might play a role in individual susceptibility to cannabis-associated psychosis. We genotyped (1) a case-control study of 272 patients with their first episode of psychosis and 234 controls, and also from (2) a sample of 252 healthy subjects, for functional variation in DRD2, rs1076560. Data on history of cannabis use were collected on all the studied subjects by administering the Cannabis Experience Questionnaire. In the healthy subjects' sample, we also collected data on schizotypy and cognitive performance using the Schizotypal Personality Questionnaire and the N-back working memory task. In the case-control study, we found a significant interaction between the rs1076560 DRD2 genotype and cannabis use in influencing the likelihood of a psychotic disorder. Among cannabis users, carriers of the DRD2, rs1076560, T allele showed a 3-fold increased probability to suffer a psychotic disorder compared with GG carriers (OR = 3.07; 95% confidence interval [CI]: 1.22-7.63). Among daily users, T carrying subjects showed a 5-fold increase in the odds of psychosis compared to GG carriers (OR = 4.82; 95% CI: 1.39-16.71). Among the healthy subjects, T carrying cannabis users had increased schizotypy compared with T carrying cannabis-naïve subjects, GG cannabis users, and GG cannabis-naïve subjects (all P ≤ .025). T carrying cannabis users had reduced working memory accuracy compared with the other groups (all P ≤ .008). Thus, variation of the DRD2, rs1076560, genotype may modulate the psychosis-inducing effect of cannabis use.

Indexed as

AdolescentAdultCannabisCase-Control StudiesDisease SusceptibilityFemaleGene-Environment InteractionHumansMaleMemory, Short-TermMiddle AgedPsychoses, Substance-InducedReceptors, Dopamine D2RiskSchizophreniaSchizotypal Personality DisorderDRD2 protein, humanReceptors, Dopamine D2dopamine receptors type 2G × E interactionschizophreniaschizotypyworking memory.

Identifiers

PMID25829376
PMCPMC4535639
OpenAlexW2040333240

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.